Bullish Player Takes Profits, Injects Fresh Optimism in Sanofi-Aventis Options

Today’s tickers: SNY, DELL, HTZ & GT SNY  - Sanofi-Aventis –  The French drug manufacturer popped up on our ‘hot by options volume’ market scanner this morning after one strategist extended bullish sentiment on the stock. Shares in Sanofi-Aventis rallied earlier in the session, but currently stand 0.35% lower on the day at $39.55 as of 11:30am in New York. The vaccines division of the pharmaceutical company, Sanofi Pasteur, said today it has received approval from the U.S. Food & Drug Administration (FDA) for its intradermal microinjection delivery system of its influenza vaccine, Fluzone. The vaccine was previously approved for intramuscular administration, but Sanofi said it plans to have the Fluzone Intradermal vaccine available to U.S. healthcare providers in time for the 2011-2012 influenza season. The bullish options trader responsible for nearly all of the day’s volume appears to be taking profits off the table on a previously established long call position. It looks like the investor originally purchased 2,000 calls at the May $37 strike for an average premium of $1.025 back on April 14 when shares in SNY were hovering around $37.54. Since the calls were purchased, shares in Sanofi rallied as much as 8.6% to touch a new 52-week high of $40.75 last Wednesday. Although shares are currently off last week’s high, the bullish trader was still able to rake in substantial profits on the long calls stance, selling all 2,000 of the May $37 strike calls this morning at a premium of $2.45 apiece. Net profits on the sale amount to $1.425 per contract. Next, the trader extended bullish sentiment on the drug maker, buying 2,000 fresh calls out at the June $40 strike for a premium of $0.40 per contract. The investor profits on the new batch of call options if shares in SNY increase 2.15% over the current price of $39.55 to surpass the effective breakeven point to the upside at $40.40 by expiration in June.…